Reference | Method of detection | Study type/ Sample size | Sensitivity/ PPA | Specificity/ NPA | Concordance/ OPA between tissue and liquid biopsy |
---|---|---|---|---|---|
Kukita Y et al. [58] | NGS amplicon-based (Ion Torrent PGM®) | Retrospective n = 155 (144 plasma and 11 other fluids) | Del 19: 73% L858R or L861Q: 78% | n.r | n.r |
Prospective n = 22 | 78% | 92% | 86% | ||
Reckamp et al. [59] | NGS Amplicon -based (Illumina MiSeq platform®) | Retrospective (TIGER-X study) N = 60 (urine and plasma) | T790M 93% L858R 100% Del19 87% (urine: T790M 72%; L858R 75% Del19 67%) | T790M 94% L858R 100% Del19 96% (urine: T790M 96%; L858R 100% Del19 94%) | n.r |
Papadimitrakopoulou V et al. [60] | Cobas® EGFR Mutation Test v2; | Retrospective analysis from AURA 3 study N = 562 | T790M: 51% L858R: 68% Del19: 82% | T790M: 77% L858R: 99% Del 19: 99% | T790M: 61% L858R: 88% Del 19: 89% |
ddPCR (Biodesix®) | T790M: 58% L858R: 70% Del19: 73% | T790M: NA L858R: 98% Del 19: 100% | n.r | ||
NGS (Guardant360®, Guardant Health) | T790M: 66% L858R: 63% Del19: 79% | T790M: NA L858R: 98% Del 19: 99% | n.r | ||
Schwartzberg et al. [61] | NGS HiSeq® 2500 (Illumina) | Prospective N = 117 | 94% | 100% | 94% |